<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02666898</url>
  </required_header>
  <id_info>
    <org_study_id>ICLL07GAI</org_study_id>
    <nct_id>NCT02666898</nct_id>
  </id_info>
  <brief_title>Phase II Trial GA101 Inbrutinib B CLL</brief_title>
  <acronym>ICLL07GAI</acronym>
  <official_title>Phase II, Multicenter, Trial, Exploring &quot;Chemo-free&quot; Treatment (GA101+Ibrutinib) and MRD-driven Strategy in Previously Untreated Symptomatic B-chronic Lymphocytic Leukemia Medically Fit A Study From the Goelams/GCFLLC/MW Intergroup</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II study testing chemo-free induction therapy with Ibrutinib + Obinutuzumab nine months&#xD;
      /&#xD;
&#xD;
      Study Part 1:&#xD;
&#xD;
      All patients will receive 8 courses of GA101 + ibrutinib 420mg PO every 28 days&#xD;
&#xD;
      Study Part 2:&#xD;
&#xD;
      After evaluation at D1 of month 9:&#xD;
&#xD;
      If patients are in CR with BM MRD &lt; 10-4, they will continue ibrutinib alone at a dose of&#xD;
      420mg daily If patients have BM MRD &gt;10-4 whatever IWCLL 2008 responses or PR they will&#xD;
      receive four courses of GA101 + FC at 28-day intervals + Ibrutinib PO until final evaluation&#xD;
      of M16&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II study testing chemo-free induction therapy with Ibrutinib + Obinutuzumab during nine&#xD;
      months followed by a MRD-driven strategy. Assessment of response as well as bone marrow MRD&#xD;
      evaluation will be performed at Day 1 month 9:&#xD;
&#xD;
        1. Patients reaching CR with marrow MRD below 10-4 threshold will continue ibrutinib during&#xD;
           6 additional months.&#xD;
&#xD;
        2. Patients in PR or bone marrow MRD &gt; 10-4 will receive Ibrutinib during 6 additional&#xD;
           months and 4 courses of FC+ GA101. At Day 1 Month 16, patients in CR but with MRD&gt; 10-4&#xD;
           will continue Ibrutinib until progressive disease.&#xD;
&#xD;
        3. Patients in stable or progressive disease will be excluded out of the trial.&#xD;
&#xD;
      Final evaluation of response (with BM MRD) will be performed at Day 1 Month 16.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study treatment response</measure>
    <time_frame>month 16</time_frame>
    <description>IWCLL criteria response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study treatment response</measure>
    <time_frame>month 16</time_frame>
    <description>MRD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>month 16</time_frame>
    <description>relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>month 16</time_frame>
    <description>death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>month 16</time_frame>
    <description>death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to next treatment</measure>
    <time_frame>36 months</time_frame>
    <description>date of new treatment after first relapse</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Leukemia, Lymphocytic, Chronic, B-Cell</condition>
  <arm_group>
    <arm_group_label>Obinutuzumab and Ibrutinib CLL treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 parts&#xD;
PART 1: 6 cycles of GA101 + Ibrutinib 420mg PO/ 28 days:&#xD;
GA101:&#xD;
C 1 D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v C 2 to 6 :D1 1000 mg i.v&#xD;
Ibrutinib:&#xD;
D3 Month 1 to Day 30 Month 15: 420mg daily PO&#xD;
PART 2: 4 cycles / 28 days&#xD;
After evaluation at D1 month 9:&#xD;
patients in CR with BM MRD &lt; 10-4, Ibrutinib 420mg daily&#xD;
patients with BM MRD &gt;10-4 or PR 4 courses of GA101 + FC/ 28-day + Ibrutinib PO until M16 Cycle 1 to 4 - GA101: 1000 mg i.v on day 1&#xD;
Fludarabine : 40 mg/m² per os, days 2-4, / 28 days&#xD;
Cyclophosphamide : 250 mg/m² per os, days 2-4, / 28 days&#xD;
Ibrutinib 420mg/day PO&#xD;
PART 3 (only in GAI-FC+Ibru arm) :&#xD;
After evaluation at D1 of M16:&#xD;
patients CR with BM MRD&lt; 10-4, treatment stopped&#xD;
patients CR with BM MRD &gt;10-4, Ibrutinib continued until PD or PB MRD becomes negative.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GA101</intervention_name>
    <description>Part 1 :6 cycles&#xD;
Obinutuzumab/GA101:&#xD;
First cycle:&#xD;
D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v&#xD;
Cycle 2 to 6 (every 28 days) :&#xD;
D1 of every cycle: 1000 mg i.v PART 2 4 cycles&#xD;
-patients have BM MRD &gt;10-4 or PR: Cycle 1 to 4 Obitinuzumab/GA101: 1000 mg i.v on day 1</description>
    <arm_group_label>Obinutuzumab and Ibrutinib CLL treatment</arm_group_label>
    <other_name>Obinutuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Part 1 :6 cycles&#xD;
Cycle 2 to 6 (every 28 days) :Ibrutinib:&#xD;
D3 Month 1 to Day 30 Month 15: 420mg daily PO PART 2:4 cycles&#xD;
patients in CR with BM MRD &lt; 10-4 : Ibrutinib alone 420mg daily&#xD;
patients with BM MRD &gt;10-4 whatever responses or PR :Cycle 1 to 4 Ibrutinib 420mg daily with Cyclophosphamide and Fludarabine</description>
    <arm_group_label>Obinutuzumab and Ibrutinib CLL treatment</arm_group_label>
    <other_name>Imbruvica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>PART 2 :&#xD;
patients with BM MRD &gt;10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days Cyclophosphamide : 250 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and fludarabine</description>
    <arm_group_label>Obinutuzumab and Ibrutinib CLL treatment</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>PART 2 :&#xD;
patients with BM MRD &gt;10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days : Fludarabine : 40 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and cyclophosphamide</description>
    <arm_group_label>Obinutuzumab and Ibrutinib CLL treatment</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient information and written informed consent&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Immunophenotypically confirmed B-CLL (IWCLL2008 and Matutes score 4 or 5)&#xD;
&#xD;
          -  Binet stage C according to IWCLL 2008 criteria or Binet stage A and B with active&#xD;
             disease could be considered for inclusion.&#xD;
&#xD;
          -  Patients with no prior treatment (chemotherapy, radiotherapy, immunotherapy) except&#xD;
             steroids for less than 1 month&#xD;
&#xD;
          -  Absence of 17p deletion as assessed by FISH (&lt; 10 % positive nuclei)&#xD;
&#xD;
          -  Performance status ECOG &lt; 2&#xD;
&#xD;
          -  CIRS (Cumulative Illness Rating Scale) ≤ 6 (see appendix 4 for calculation of CIRS&#xD;
             score) Mandatory inclusion criteria for treatment with ibrutinib&#xD;
&#xD;
        Hematology values must be within the following limits:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt;1 G/L independent of growth factor support&#xD;
&#xD;
          -  Platelets &lt;100 G/L or &lt;50 G/L if bone marrow involvement independent of transfusion&#xD;
             support in either situation&#xD;
&#xD;
        Biochemical values within the following limits:&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit&#xD;
             of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of&#xD;
             non-hepatic origin&#xD;
&#xD;
          -  Serum creatinine ≤ 2 x ULN or estimated Glomerular Filtration Rate (Cockroft Gault≥ 40&#xD;
             mL/min/1.73m2&#xD;
&#xD;
          -  Women of childbearing potential and men who are sexually active must be practicing a&#xD;
             highly effective method of birth control during and after the study consistent with&#xD;
             local regulations regarding the use of birth control methods for subjects&#xD;
             participating in clinical trials. Men must agree to not donate sperm during and after&#xD;
             the study. For females, these restrictions apply for 1 month after the last dose of&#xD;
             study drug. For males, these restrictions apply for 3 months after the last dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum (beta-human chorionic&#xD;
             gonadotropin [Beta-hCG]) or urine pregnancy test at Screening. Women who are pregnant&#xD;
             or breastfeeding are ineligible for this study.&#xD;
&#xD;
          -  Sign (or their legally-acceptable representatives must sign) an informed consent&#xD;
             document indicating that they understand the purpose of and procedures required for&#xD;
             the study, including biomarkers, and are willing to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Binet stage A and B without active disease according to IWCLL 2008 criteria&#xD;
&#xD;
               -  Known HIV seropositivity&#xD;
&#xD;
               -  Hepatitis B or C seropositivity (unless clearly due to vaccination)&#xD;
&#xD;
               -  Active hemolysis (isolated positive DAT is not an exclusion criteria)&#xD;
&#xD;
               -  Life expectancy &lt; 6 months&#xD;
&#xD;
               -  Patient refusal to perform the bone marrow biopsy for evaluation points&#xD;
&#xD;
               -  Clinically significant auto-immune anemia&#xD;
&#xD;
               -  Active second malignancy currently requiring treatment (except basal cell&#xD;
                  carcinoma in situ endometrial carcinoma and incidental prostate carcinoma) and/or&#xD;
                  less than 5 years CR after breast cancer&#xD;
&#xD;
               -  Any severe co-morbid conditions such as Class III or IV heart failure, myocardial&#xD;
                  infarction within months, unstable angina, ventricular tachyarrhythmias requiring&#xD;
                  ongoing treatment, severe chronic obstructive pulmonary disease with hypoxemia,&#xD;
                  uncontrolled diabetes mellitus, or uncontrolled hypertension&#xD;
&#xD;
               -  Concomitant disease requiring prolonged use of corticosteroids (&gt; 1 month)&#xD;
&#xD;
               -  Known hypersensitivity with anaphylactic reaction to humanized monoclonal&#xD;
                  antibodies or any of the study drugs&#xD;
&#xD;
               -  Contraindication to the use of Obinutuzumab.&#xD;
&#xD;
               -  Contraindication to use of Ibrutinib&#xD;
&#xD;
               -  Transformation to aggressive B-cell malignancy (e.g. diffuse large cell lymphoma,&#xD;
                  Hodgkin lymphoma, or prolymphocytic leukaemia)&#xD;
&#xD;
               -  Active bacterial, viral or fungal infection&#xD;
&#xD;
               -  Abnormal renal function with creatinine clearance &lt; 60 ml/min calculated&#xD;
                  according to the formula of Cockcroft and Gault&#xD;
&#xD;
               -  Total bilirubin, gamma glutamyltransferase or transaminase levels &gt; 2.5 ULN.&#xD;
&#xD;
               -  Any coexisting medical or psychological condition that would preclude&#xD;
                  participation in the required study procedures&#xD;
&#xD;
               -  Patient with mental deficiency preventing proper understanding of the&#xD;
                  requirements of treatment.&#xD;
&#xD;
               -  Pregnant or breastfeeding women.&#xD;
&#xD;
               -  Adult under law-control&#xD;
&#xD;
               -  Fertile male and female patients who cannot or do not wish to use an effective&#xD;
                  method of contraception, during and for 18 months after the final treatment used&#xD;
                  for the purposes of the study.&#xD;
&#xD;
               -  No affiliate to social security&#xD;
&#xD;
        Mandatory exclusion criteria for treatment with Ibrutinib&#xD;
&#xD;
          -  Major surgery within 4 weeks of randomization.&#xD;
&#xD;
          -  Known central nervous system lymphoma.&#xD;
&#xD;
          -  History of stroke or intracranial hemorrhage within 6 months prior to randomization.&#xD;
&#xD;
          -  Requires anticoagulation with warfarin or equivalent vitamin K antagonists&#xD;
&#xD;
          -  Requires treatment with strong CYP3A inhibitors.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease such as uncontrolled or symptomatic&#xD;
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of&#xD;
             Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by&#xD;
             the New York Heart Association Functional Classification.&#xD;
&#xD;
          -  Vaccinated with live, attenuated vaccines within 4 weeks of randomization.&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) or active Hepatitis C Virus or&#xD;
             active Hepatitis B Virus infection or any uncontrolled active systemic infection&#xD;
             requiring intravenous (IV) antibiotics.&#xD;
&#xD;
          -  Any life-threatening illness, medical condition, or organ system dysfunction which, in&#xD;
             the investigator's opinion, could compromise the subject's safety, interfere with the&#xD;
             absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue&#xD;
             risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie ROUILLE, Mrs</last_name>
    <role>Study Director</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre FEUGIER, MD PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Sophie MICHALLET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sponsor FILO</name>
      <address>
        <city>Tours</city>
        <zip>37054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.filo-leucemie.org</url>
    <description>FILO internet site</description>
  </link>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 26, 2015</study_first_submitted>
  <study_first_submitted_qc>January 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2016</study_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Residual disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

